Watch the video and download the slides
GU cancer update by Dr. Elena Castro, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Oncology
GU CONNECT Update from ESMO 2021
GU cancer update by Dr. Elena Castro, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
Publication Date
Oct 2021
Hi my name is Elena Castro, I’m a medical oncologist at Hospital Universitario Virgen de la Victoria in Malaga in Spain and I’m going to comment on some abstracts presented at ESMO 2021 that I believe are very relevant for our clinical practice.
Which abstracts did you select and why?
I have selected two abstracts presented in the presidential symposium.
The first one by Dr. Attard who presented on patients with high-risk localised disease included in the STAMPEDE trial treated with abiraterone with or without enzalutamide.
The second abstract was presented by Dr. Fizazi, he presented data on the addition of abiraterone for the treatment of patients with metastatic hormone-sensitive prostate cancer, who may also have received docetaxel.
He has already presented data on radiographic progression free survival earlier at ASCO this year but here he has presented overall survival data.
What are the main conclusions?
The main conclusion of the STAMPEDE data presented here is that patients with high risk localised prostate cancer benefit from the addition of two years of treatment with abiraterone.
The conclusion of the PEACE-1 study presented at ESMO 2021 is that patients with metastatic hormone-sensitive prostate cancer, particularly those with high volume disease benefit from intensified therapy with docetaxel and abiraterone.
What are the implications of this data for clinical practice?
What we’ve learned from the data presented from STAMPEDE and PEACE-1 is that for patients with a higher risk of progression, either in the localised setting or in the metastatic hormone-sensitive setting, intensifying therapies can improve their survival.
Were there any other presentations of interest?
Dr. Armstrong has presented the final survival data of the ARCHES trial that demonstrates the benefits of treating patients with metastatic hormone-sensitive prostate cancer with enzalutamide and is in line with the results of other trials addressing the benefit of other androgen receptor inhibitors in this setting.
And also a study from the Swiss group in which the investigators assess the role of continuous daralutamide after treatment with docetaxel in patients with metastatic castration-resistant prostate cancer.
What are your take-home messages from ESMO 2021?
I believe that from now on we will be using the androgen receptor signaling inhibitors more and more in earlier stages and we have more and more evidence that suggests that sequencing these therapies is probably not the best approach for our patients but as we have seen at ESMO, there are many other drugs that are being investigated for mCRPC and we are likely to be using these new therapies with new mechanisms of actions in the advanced stages.
On behalf of GU CONNECT, thank you for listening and don’t forget to visit the COR2ED website if you would like to download the slides.
Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain. She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain. After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK. Later, she joined the Spanish National Cancer Research Center as a clinician-scientist. Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.
Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix.
Episode
1
of
Experts
Assoc. Prof. Tanya Dorff-
Downloadable
Resouces -
5 MIN
-
Oct 2021 -
Episode
1
of
Experts
Assoc. Prof. Alicia Morgans-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Experts
Prof. Neeraj Agarwal-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Experts
Dr Fabio Schutz-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Experts
Prof. Gerhardt Attard-
Downloadable
Resouces -
5 MIN
-
Oct 2021
-
Programme summary
Duration 5 MIN
Downloadable resources Yes-
DOWNLOAD SLIDES - PPTX
-
DOWNLOAD SLIDES - PDF
-
Language(s)
Share this programme
Brought to you by
GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the experts
Other programmes of interest
Video
Oncology
Recent advances in precision oncology and future implications
Two emerging and two established targets
Experts
Prof. David Hong-
Downloadable
Resources -
4 MIN
-
Dec 2024
Publication
Oncology
Survey on the evolving role of the oncology nurse in the USA
Announcing the publication of survey results
Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo-
Downloadable
Resources -
10 MIN
-
Dec 2024
Video
Oncology
Elacestrant in ER+/HER2- metastatic breast cancer
An expert overview of the EMERALD subgroup analysis
Experts
Dr Virginia Kaklamani-
Downloadable
Resources -
4 MIN
-
Dec 2024
Video
Oncology
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)
Managing patients with nccRCC: guidelines, recommendations, and best practice
Experts
Prof. Laurence AlbigesEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Micro learning
Oncology
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment
Risk factors, diagnostic tools and treatment options for different patient groups
Experts
Prof. Efrat Dotan, Prof. Shubham PantEndorsed by
-
Downloadable
Resources -
4 MIN
-
Dec 2024
Conference update
Oncology
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update
Exploring emerging treatment strategies presented at SABCS 2024
Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava-
Downloadable
Resources -
5 MIN
-
Dec 2024
